Ingredient or product comparison
Subcutaneous Injection vs Topical Application
Subcutaneous GHK-Cu administration bypasses the stratum corneum entirely, delivering the peptide directly to dermal fibroblasts at concentrations 10–20× higher than topical application achieves. Injection protocols used in research settings typically involve 2
This source-based comparison does not add ratings or recommend a winner.
- Subcutaneous GHK-Cu administration bypasses the stratum corneum entirely, delivering the peptide directly to dermal fibroblasts at concentrations 10–20× higher than topical application achieves. Injection protocols used in research settings typically involve 2–5 mg GHK-Cu dissolved in bacteriostatic saline, administered via 30-gauge insulin syringe into targeted areas (nasolabial folds, under-eye hollows, forehead lines). Visible improvements. Reduced fine line depth, improved skin turgor. Appear within 2–3 weeks at this dose.
- The trade-off is injection site management. GHK-Cu stimulates angiogenesis (new blood vessel formation) as part of its wound-healing cascade, which occasionally causes temporary localized redness or minor bruising at injection sites. This resolves within 48–72 hours but requires technique precision. Injecting too superficially (into the epidermis rather than the dermis) wastes peptide and increases irritation risk.
- Our experience working with labs conducting peptide delivery research shows that reconstitution technique determines peptide stability post-mixing. Real Peptides supplies research-grade GHK-Cu as lyophilized powder, which remains stable at −20°C for 24+ months. Once reconstituted with bacteriostatic water, the solution must be refrigerated at 2–8°C and used within 28 days. Copper ions catalyze oxidative degradation at room temperature, turning the solution from clear blue to greenish-brown (a visible sign of peptide breakdown). Subcutaneous delivery requires this level of handling discipline; topical products pre-formulated in stabilized bases eliminate that variable.